aminopyrine has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ledermann, M; Neef, M; Reichen, J; Saegesser, H; Schneider, V | 1 |
2 other study(ies) available for aminopyrine and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.
Topics: Administration, Oral; Aminopyrine; Animals; Blotting, Western; Breath Tests; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Matrix; Gene Expression; Immunosuppressive Agents; Liver Cirrhosis, Experimental; Male; Matrix Metalloproteinase 2; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Survival Rate; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Treatment Outcome | 2006 |